Company Summary:
Tessera Therapeutics is pioneering Gene Writing™— a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
Position Summary:
The Senior Research Associate will work closely with scientists in the ex vivo team to translate novel gene writing technologies to develop innovative therapeutics for hematological disorders. We are searching for a driven, enthusiastic and self-motivated individual who is comfortable multitasking and working independently on various aspects of the platform. This individual will join a dynamic, rapidly growing, and highly collaborative team.
Key Responsibilities:
- Perform in vitro studies to evaluate and validate novel gene writing technologies in human hematopoietic stem and progenitor cells (HSPCs)
- Purify genomic DNA and RNA for gene writing efficiency analysis
- Perform assays to characterize the phenotype of gene modified HSPCs
- Make detailed observations, analyze, and interpret data
Basic Qualifications:
- Master’s degree in biological sciences with 2+ years postgraduate experience
- Extensive hands-on experience in tissue culture of cell lines and primary cells
- Previous experience with flow cytometry
- Quick learner and team player
Preferred Qualifications:
- Experience with human HSPC or T cell culture and manipulation
- Experience in non-viral or viral gene delivery methods, including electroporation, nucleofection and viral transduction
More About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $50B in aggregate value. To date, Flagship has deployed over $2.2B in capital toward the founding and growth of its pioneering companies alongside more than $18B of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology, Seres Therapeutics (NASDAQ: MCRB), and Sigilon Therapeutics (NASDAQ: SGTX).
Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.
Recruitment & Staffing Agencies: Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.